FSD Pharma [HUGE] vs Zoetis [ZTS] Detailed Stock Comparison

FSD Pharma Inc.

NASDAQ
Loading...

Zoetis Inc.

NYSE
Loading...

TLDR: Quick Comparison Summary

Based on 21 vital metrics comparison: FSD Pharma Inc. wins in 2 metrics, Zoetis Inc. wins in 12 metrics, with 0 ties. Zoetis Inc. appears stronger overall.

View Metrics Details

Vital Metrics Comparison

Metric FSD Pharma Inc. Zoetis Inc. Better
P/E Ratio (TTM) -0.18 19.58 Zoetis Inc.
Price-to-Book Ratio 0.01 15.04 FSD Pharma Inc.
Debt-to-Equity Ratio 6.13 279.59 FSD Pharma Inc.
PEG Ratio -0.75 2.81 Zoetis Inc.
EV/EBITDA -0.03 13.96 Zoetis Inc.
Profit Margin (TTM) 0.00% 28.24% Zoetis Inc.
Operating Margin (TTM) 0.00% 34.69% Zoetis Inc.
EBITDA Margin (TTM) N/A 34.69% N/A
Return on Equity -63.89% 65.99% Zoetis Inc.
Return on Assets (TTM) -36.47% 15.26% Zoetis Inc.
Free Cash Flow (TTM) $-10.83M $2.28B Zoetis Inc.
Dividend Yield N/A 1.21% N/A
1-Year Return -92.53% -51.58% Zoetis Inc.
Price-to-Sales Ratio (TTM) N/A 5.26 N/A
Enterprise Value $287,159 $56.75B Zoetis Inc.
EV/Revenue Ratio N/A 6.00 N/A
Gross Profit Margin (TTM) N/A 70.17% N/A
Revenue per Share (TTM) $0 $21 Zoetis Inc.
Earnings per Share (Diluted) $-16.25 $6.02 Zoetis Inc.
Beta (Stock Volatility) N/A 0.97 N/A
Short % of Float N/A 4.06% N/A

FSD Pharma Inc. vs Zoetis Inc. Stock Performance Analysis

Loading Price Chart...

HUGE
ZTS

Performance Comparison

Short-term Returns

Stock1D1W1M3M6MYTD
FSD Pharma Inc.12.29%N/AN/AN/AN/AN/A
Zoetis Inc.1.51%0.16%3.42%-31.08%-32.94%-36.81%

Long-term Returns

Stock1Y3Y5Y10Y15Y20Y
FSD Pharma Inc.-92.53%-94.20%-98.33%-99.52%-99.52%-99.52%
Zoetis Inc.-51.58%-53.40%-57.08%71.34%156.59%156.59%

Performance & Financial Health Analysis: FSD Pharma Inc. vs Zoetis Inc.

MetricHUGEZTS
Market Information
Market Cap iN/A$49.75B
Market Cap CategoryN/ALarge cap
10 Day Avg. Volume i82,6632,727,710
90 Day Avg. Volume i62,7793,835,940
Last Close$5.39$167.10
52 Week Range$3.50 - $97.50$139.70 - $200.33
% from 52W High-94.47%-16.59%
All-Time High$11,432.16 (Sep 10, 2018)$249.27 (Dec 27, 2021)
% from All-Time High-99.95%-32.96%
Growth Metrics
Quarterly Revenue GrowthN/A0.03%
Quarterly Earnings GrowthN/A0.04%
Financial Health
Profit Margin (TTM) i0.00%0.28%
Operating Margin (TTM) i0.00%0.35%
Return on Equity (TTM) i-0.64%0.66%
Debt to Equity (MRQ) i6.13279.59
Cash & Liquidity
Book Value per Share (MRQ)$17.09$7.84
Cash per Share (MRQ)$5.19$5.48
Operating Cash Flow (TTM) i$-5,144,110$2.90B
Levered Free Cash Flow (TTM) i$-10,054,595$1.79B
Dividends
Last 12-Month Dividend Yield iN/A1.21%
Last 12-Month Dividend iN/A$2.03

Valuation & Enterprise Metrics Analysis: FSD Pharma Inc. vs Zoetis Inc.

MetricHUGE (Mar 31, 2025)ZTS (Apr 13, 2026)
Price Ratios
P/E Ratio (TTM) i-0.1819.58
Forward P/E i-0.7515.61
PEG Ratio i-0.752.81
Price to Sales (TTM) iN/A5.26
Price to Book (MRQ) i0.0115.04
Market Capitalization
Market Capitalization i$66,671$49.75B
Enterprise Value i$287,159$56.75B
Enterprise Value Metrics
Enterprise to Revenue iN/A6.00
Enterprise to EBITDA i-0.0313.96
Risk & Other Metrics
Beta iN/A0.97
Book Value per Share (MRQ) i$17.09$7.84

Financial Statements Comparison: FSD Pharma Inc. vs Zoetis Inc.

Financial Metrics

Loading Financial Charts...

Revenue

Operating Margin

Profit Margin

Long Term Debt

Income Flow Analysis

Financial Statements Comparison

Income Statement

MetricHUGE (2023)ZTS (2025)
Revenue/Sales i09.47B
Cost of Goods Sold iN/A2.67B
COGS % of Revenue i-28.2%
Gross Profit iN/A6.80B
Gross Margin i-71.8%
Research & Development i3.86M698.00M
Operating Income (EBIT) i-19.57M3.60B
Operating Margin i-38.0%
EBITDA i-11.34M4.17B
EBITDA Margin i-44.1%
Pre-Tax Income i-18.23M3.36B
Pre-Tax Income % of Revenue i-35.5%
Income Tax iN/A687.00M
Income Tax % of Revenue i-7.3%
Net Income (Profit) i-18.23M2.67B
Profit Margin i-28.2%

Balance Sheet & Liquidity Metrics

MetricHUGE (2023)ZTS (2025)
Cash & Equivalents i2.76M2.31B
Total Current Assets i11.09M6.77B
Total Current Assets % of Revenue i-71.5%
Total Current Liabilities i4.57M2.24B
Total Current Liabilities % of Revenue i-23.6%
Long-Term Debt i09.24B
Long-Term Debt % of Revenue i-97.6%
Total Shareholders Equity i12.91M3.33B
Retained Earnings i-157.91M13.74B
Retained Earnings % of Revenue i-145.2%
Property, Plant & Equipment i120,421288.00M

Cash Flow Statement Comparison

MetricHUGE (2023)ZTS (2025)
Operating Cash Flow i-17.53M2.78B
Operating Cash Flow % of Revenue i-29.3%
Capital Expenditures i0N/A
Free Cash Flow i-10.83M2.28B
FCF Margin i-24.1%
Debt Repayment i-189,054-1.35B
Common Stock Repurchase i-2.96M-3.24B

Short Interest & Institutional Ownership Analysis

MetricHUGEZTS
Shares Short iN/A15.12M
Short Ratio iN/A3.60
Short % of Float iN/A4.06%
Shares Outstanding i605,796424.93M
Float Shares i600,696421.29M
% Held by Insiders i9.74%0.15%
% Held by Institutions i2.69%101.50%
% Held by Public i87.57%-1.65%

Dividend Analysis & Yield Comparison: FSD Pharma Inc. vs Zoetis Inc.

MetricHUGEZTS
Last 12-Month Dividend iN/A$2.03
Last 12-Month Dividend Yield iN/A1.21%
3-Year Avg Annual Dividend iN/A$1.80
3-Year Avg Dividend Yield iN/A0.29%
3-Year Total Dividends iN/A$5.39
Ex-Dividend DateN/AJan 20, 2026